Edwards Lifesciences Corp
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Comprehensive Income
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net income | $3,069.4 | $383.7 | $3,785.4 | $1,029.7 |
| Other comprehensive (loss) income, net of tax (Note 14): | ||||
| Foreign currency translation adjustments | 4.3 | (23.4) | (20.8) | (31.1) |
| Unrealized (loss) gain on hedges | (42.7) | 18.2 | (8.9) | 6.3 |
| Unrealized pension credits | — | — | 0.2 | 0.1 |
| Unrealized gain on available-for-sale investments | 6.1 | 10.6 | 19.8 | 29.5 |
| Other comprehensive (loss) income, net of tax | (32.3) | 5.4 | (9.7) | 4.8 |
| Comprehensive income | 3,037.1 | 389.1 | 3,775.7 | 1,034.5 |
| Comprehensive loss attributable to noncontrolling interest | (1.4) | (1.2) | (3.6) | (2.8) |
| Comprehensive income attributable to Edwards Lifesciences Corporation | $3,038.5 | $390.3 | $3,779.3 | $1,037.3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.